OCS

Oculis Holding AG is a pioneering biopharmaceutical company located in Zug, Switzerland, dedicated to transforming the treatment landscape for ophthalmic diseases through its innovative topical therapies. Utilizing cutting-edge formulation technologies, Oculis targets significant unmet medical needs in vision care, aiming to improve patient outcomes with convenient and effective therapies. With a strong pipeline of products addressing both acute and chronic eye conditions, the company is well-positioned to make a substantial impact in the ophthalmology sector, thus attracting the attention of institutional investors seeking opportunities in novel therapeutic solutions.